ANGELA RESCH: Open Payments
NPI 1598748386 · LEAVENWORTH, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,057 in 125 payments from 24 companies in 2025. Trend: 2023 $1,845 · 2024 $1,887 · 2025 $2,057
Food & beverage: $2,057
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 25 | $309 |
| Novo Nordisk Inc | 14 | $243 |
| ABBVIE INC. | 21 | $217 |
| Lilly USA, LLC | 8 | $164 |
| AstraZeneca Pharmaceuticals LP | 5 | $147 |
| Novartis Pharmaceuticals Corporation | 7 | $115 |
| Astellas Pharma US Inc | 3 | $91 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Abbott Laboratories | 4 | $86 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $79 |
Products named: UBRELVY, LEQVIO, NURTEC ODT, JARDIANCE, FARXIGA, MOUNJARO, Veozah, Wegovy.
Industry payments across KS — which companies pay providers there.
